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Abstract
Aims To describe the characteristics and time to death of patients with breast or haematological cancer who died of heart
failure (HF) after cancer therapy. Patients with an index admission for HF who died of HF-related causes (IAHF) and those with
no index admission for HF who died of HF-related causes (NIAHF) were compared.
Methods and results We performed a linked data analysis of cancer registry, death registry, and hospital administration
records (n = 15 987). Index HF admission must have occurred after cancer diagnosis. Of the 4894 patients who were de-
ceased (30.6% of cohort), 734 died of HF-related causes (50.1% female) of which 279 (38.0%) had at least one IAHF
(41.9% female) post-cancer diagnosis. Median age was 71 years [interquartile range (IQR) 62–78] for IAHF and 66 years
(IQR 56–74) for NIAHF. There were fewer chemotherapy separations for IAHF patients (median = 4, IQR 2–9) compared
with NIAHF patients (median = 6, IQR 2–12). Of the IAHF patients, 71% had died within 1 year of the index HF admission.
There was no signiﬁcant difference in HF-related mortality in IAHF patients compared with NIAHF (HR, 1.10, 95% CI, 0.94–
1.29, P = 0.225).
Conclusions The proﬁle of IAHF patients who died of HF-related causes after cancer treatment matched the current proﬁle
of HF in the general population (over half were aged ≥70 years). However, NIAHF were younger (62% were aged ≤69 years),
female patients with breast cancer that died of HF-related causes before hospital admission for HF-related causes—a group
that may have been undiagnosed or undertreated until death.
Keywords Cardiotoxicity; Mortality; Haematological; Breast; Cancer; Heart failure
Received: 4 February 2016; Revised: 20 May 2016; Accepted: 30 May 2016
*Correspondence to: Robyn A. Clark PhD, School of Nursing and Midwifery, Flinders University, GPO Box 2100 Adelaide 5001, SA, Australia. Tel: +61 8 82013266.
Email:robyn.clark@ﬂinders.edu.au
Introduction
Anticancer therapies have increased recurrence-free survival
for many patients with cancer. However, associated comor-
bidities and treatment-related toxicity have limited overall
survival gains.1 Cardiotoxicity is one of the most signiﬁcant
side effects of some anticancer agents, so that any gain in life
expectancy is potentially diminished by increased mortality
because of cardiotoxic sequelae such as heart failure (HF),
myocardial ischaemia, arrhythmias, hypertension, and
thromboembolism.1
The incidence and outcomes of cardiotoxicity depend on
different factors related to oncological therapies including the
type of drug, the mode of administration (i.e. bolus or
continuous), dose administered during each cycle, cumulative
dose, combinations (or prior treatment) with other cardiotoxic
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drugs or radiotherapy of the cardiac region and patient age,
mediastinal radiation, female sex, and presence of cardiovascular
risk factors and previous cardiovascular disease.2,3
Cardiotoxicity related to anthracyclines is well documented,
with early studies reporting variable rates, often based upon
retrospective identiﬁcation in cancer survivor cohorts. A recent
large, prospective study, which included regular monitoring of
cardiac function, reported an incident rate of cardiotoxicity
following anthracycline therapy of 9% over a median 5-year
follow-up period,3 with 98% of these cases occurring in the ﬁrst
12months. High mortality rates have also been reported in
patients with anthracycline-mediated cardiotoxicity identiﬁed
through historical longitudinal cohorts.4 More recent studies
have suggested better cardiac-related survival of chemo-
therapy patients, especially in patients identiﬁed with pre-
symptomatic left ventricular dysfunction.5 This is likely to be
a result of routine baseline and ongoing monitoring being
implemented as standard practice where known cardiotoxic
drugs are considered.5 Cardinale et al. (2015) recently reported
that left ventricular function either partially or completely
recovered following early detection and treatment in 82% of
patients with anthracycline-mediated cardiotoxicity.3 Torti
and colleagues,6 based on histologic evidence of anthracycline
cardiotoxicity, showed that only higher doses and frequency of
anthracycline administration and previous cardiac irradiation
were independent risk factors. Cumulative doxorubicin dose
was also recently conﬁrmed to be an independent risk factor
by Cardinale et al. (2015), in addition to end-chemotherapy left
ventricular ejection fraction. Nonetheless, there is wide
variation in individual sensitivity to anthracyclines, with some
patients developing cardiotoxicity at doses as low as
300mg/m2 body surface area.3
Previous work from our research group, using a linked
dataset, demonstrated that in those individuals with breast
or haematological cancer (leukaemias, lymphomas, and
related blood disorders), 7% of patients previously treated
with chemotherapy had an index hospital admission for HF
(1062/15 987) within the 14-year study period (Figure 1).7
Of these patients who had an index admission for HF,
68% (728/1062) died within the study period, with 38%
Figure 1 Population selection ﬂow diagram. This diagram displays the initial study population through to the ﬁnal study population.
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(279/728) of deaths attributed to HF-related causes.
Approximately 93% (14 925/15 987) of individuals did not
have an index admission for HF following chemotherapy.
Of these patients, 28% (4166/14 925) had died, with
approximately 11% (455/4166) of deaths attributed to
HF-related causes. Individuals who had no previous index
HF admission were signiﬁcantly younger and comprised a
greater proportion of females compared with patients
admitted with HF.7 This group was the focus of this study.
The aim of this sub-analysis was to further explore the charac-
teristics of those patients who died of HF-related causes after
chemotherapy. As 11% of the cohort described in the previously
mentioned died of HF-related causes without an index hospital
admission for HF, the objectives of this study were to
(1) Identify differences in demographic characteristics between
those who died of HF-related causes after an index
admission for HF (IAHF), compared with those who died of
HF-related causes without an index admission for HF
(NIAHF) and
(2) Identify whether there were differences in HF-related
mortality risk between the two patient groups.
Methods
Study design and setting
This is a retrospective cohort study of patients linked using
health data between January 1996 and December 2009 from
Queensland, Australia. Queensland is Australia’s third most
populous state with an estimated residential population of four
million people during the study period.8 This time frame enabled
linkage and analysis of uniform data across the three data
sources relating to morbidity, hospitalization, and mortality.
Ethics approval was granted by the Metro South Service
District Human Research Ethics Committee on behalf of the
Queensland Government (HREC/11/QPAH/600).
Assumptions of this analysis
The purpose of this analysis was to review the characteristics
of patients who died of HF after cancer treatment. We used
‘real-world’ data from clinical administration datasets using
data linkage techniques. Data for cardiovascular risk factors,
previous disease, and details on speciﬁc dose and chemo-
therapy agents were not available or obtainable during the
process of data abstraction and linkage. Therefore, as a
surrogate variable to control for confounders (such as a
previous diagnosis of HF), we examined the outcomes of
patients who had their ﬁrst HF admission after chemo-
therapy. An index HF admission is the ﬁrst-ever recorded
admission as coded on discharge using ICD9 of International
Classiﬁcation of Diseases and Tenth Revision (ICD10) codes
for the classiﬁcation of HF. This is regarded as an acceptable
criterion for diagnostic conﬁrmation of HF.9 The comparison
group may have contained patients with existing HF.
The second assumption of this analysis is that patients
with breast or haematological cancers were more likely than
patients with other cancers to be treated with cardiotoxic
drugs, particularly anthracyclines.3
Thirdly, while chemotherapy is usually delivered in the
outpatient setting, ambulatory care of this nature is often
recorded as an admission for chemotherapy, which we have
used as a surrogate for the number of chemotherapy cycles.
The assumption of this variable is that all patients in the cohort
received chemotherapy for haematological and breast cancer
from 1996 to 2009 but that not all chemotherapy cycles have
been captured. Outpatient and pharmacotherapy data were
not available for linkage at the time of our data request.
Participants
Primary cancer diagnosis was used to identify the cancer
site/morphology using the ICD19 Australian Modiﬁcation
(ICD10-AM) and Oncology ICD-O site codes in the original linked
dataset. Cancer sites were deﬁned as breast (ICD10-AM: C50) or
haematological (leukemia, lymphoma, and related disorders)
(ICD10-AM: C42, C77 and ICD-O:M9590/3-M9989/3) henceforth
referred to as ‘haematological cancers’. No age exclusions were
applied. In this analysis, only patients who had died of HF-related
causes were included, and these patients were then stratiﬁed
into two groups—those who had their ﬁrst admission/diagnosis
for HF as identiﬁed by an IAHF and those who did not have an
index HF admission (NIAHF), following commencement of
chemotherapy.
Data sources and linkage
Data were accessed from the Queensland Cancer Registry,
the Hospital Admitted Patient Data Collection, and the
Queensland Births, Deaths, and Marriages database.
The Queensland Cancer Registry was used to access data
on age, sex, marital status, residence (rural or metropolitan),
country of birth, and Aboriginal or Torres Strait Islander
status. Primary cancer diagnosis was used to identify the
cancer type, and the cancer site/morphology was identiﬁed
by applying the relevant site codes from ICD9 and ICD10.
Patients receiving chemotherapy were identiﬁed by using
chemotherapy-related procedure codes from the Hospital
Patient Data Collection and linked to the primary cancer
diagnoses records from the Queensland Cancer Registry.
The procedure codes were deﬁned according to ICD Clinical
Modiﬁcation (ICD-9CM) and ICD10-AM. Cancer morphology
codes were deﬁned in accordance with uniform ICD-O.
Radiotherapy was not considered in this study because of
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the unknown proportion of patients receiving concomitant
treatment in an outpatient setting.
Selection of patients with an index HF hospitalization was
based upon hospital records with patients ﬂagged if they
had an admission to hospital for the ﬁrst time with HF coded
as the principle diagnosis (i.e. ICD9-CM and ICD10-AM
diagnostic codes). This ﬁrst admission or ‘index event’ must
have occurred after the diagnosis of cancer and the
commencement of chemotherapy.
The third database involved in the linkage process was the
Queensland Birth, Deaths, and Marriages database—a
complete repository of all registered deaths in the state of
Queensland. All causes of death underwent a manual
recoding from the text entries—a process that underwent
quality assurance by three independent investigators. The
end date of data for study purposes was 31 December
2009. Deaths after this date were not accounted for, and
the patients alive at the speciﬁed end date were considered
alive for the purposes of calculating survival times and
mortality analyses. Data extraction and coding were under-
taken using STATA 13.0. Linkage Wiz software was used to
undertake probabilistic record matching. Quality control
undertaken during the linkage process included a 20-step
manual clerical review to identify false positives—a method
that quantiﬁed the false positive rate at 0.3%.9
Statistical analyses
Based upon the stratiﬁcation of patients as (i) an index HF
admission (IAHF) and (ii) no admission for HF (NIAHF), admission
groups were compared using χ2-contingency table testing for
categorical variables (age group, sex marital status, country of
birth, Indigenous status, residence, cancer morphology/site).
Age in years was categorized as <20, 20–29, 30–30, 40–49,
50–59, 60–69, and ≥70 to describe the demographics of the
study population and is also presented as a continuous variable.
Because of the non-normal distribution of the continuous
variables (age, hospitalizations, chemotherapy treatments), they
are presented as medians with interquartile range (IQR) and
compared using the non-parametric Mann–Whitey U test. The
effect of an IAHF on the risk of HF mortality was assessed
adjusted for age, sex, marital status, country of birth, cancer site,
and chemotherapy along with other confounders using a time-
varying Cox proportional hazards regression model. Multivariate
adjustment was undertaken for the covariates of age group in
years [<20, 20–29, 30–30, 40–49, 50–59, 60–69, and ≥70], sex,
marital status, country of birth, cancer site, and number of
chemotherapy separations categorized as quintiles [Q1: 1–3;
Q2: 4–6; Q3: 7–9; Q4: 10–16; Q5: ≥17]. To examine associations
between admission groups, an adjusted Kaplan–Meier survival
analysis was used with a log-rank test. All statistical tests were
conducted at the 5% signiﬁcance level andwere performed using
IBM SPSS 22.0.
Results
Participants
A Strengthening the Reporting of Observational studies in
Epidemiology ﬂow chart describes the allocation of patients to
the respective groups for the subsequent analyses (Figure 1).10
A total of 73158 patients from the cancer registry were able
to be record-matched with hospital administration records and
mortality data.
Of these, 918 were diagnosed with multiple cancers. To avoid
duplicating patients in the analyses, the primary cancer diagnosis
was chosen and the remaining registrations of subsequent can-
cers in this group were excluded (n=927). A further 15750 were
excluded as they fell outside the study time period, and another
40494 were excluded as they did not receive chemotherapy.
The remaining 15 987 patients were then identiﬁed as
those who had an index HF admission (n = 1062) or those
who did not have an index HF admission (n = 14 925).
Within each of these groups, those with HF-related death
within the study period were identiﬁed, resulting in the two
groups analysed in this study: those with a diagnosed index
HF admission who died of HF-related causes (IAHF, n = 279)
and those with no index HF admission but who died of HF-
related causes (NIAHF, n = 455).
Demographics and characteristics
Within the deceased group, the median age at cancer diagnosis
was 71 and 66years for the IAHF and NIAHF patients,
respectively (Table 1, P< 0.001). There was a signiﬁcant
association between age group and HF admission status
between these two groups, with the majority of HF patients
being ≥70years, while the NIAHF were more evenly spread
across the younger age groups (χ2 =32.05, df =6, P< 0.001).
Gender (χ2 =12.11, df =1, P=0.001) and cancer
morphology/site (χ2 =25.57, df =1, P< 0.001) were also signi-
ﬁcantly different between the two groups, as were the median
number of overall hospitalizations for HF or chemotherapy
(P< 0.001) and median number of chemotherapy admissions
(P< 0.001). All other comparisons were non-signiﬁcant.
Outcomes
There was no signiﬁcant difference in HF-related mortality in
IAHF patients compared with NIAHF (HR, 1.10, 95% CI, 0.94–
1.29, P = 0.225) (Figure 2) when adjusted for age, sex, marital
status, country of birth, cancer site, and number of chemo-
therapy treatments.
In the NIAHF group, individuals diagnosed with haematologi-
cal cancer were almost 1.5 times more likely to die of HF-related
causes than patients with breast cancer (P=0.006) (Table 2).
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A similar odds ratio was evident in the IAHF patients but
was non-signiﬁcant. The only other signiﬁcant difference
was that those in the IAHF group received four to six admis-
sions for chemotherapy compared with those who had one
to three admissions (Table 2). All other covariates were
non-signiﬁcant in the adjusted models.
Of those who died of HF-related causes, 31% of IAHF and
33% of NIAHF patients died within the ﬁrst year after the
cancer diagnosis and 60% of IAHF and 62% of NIAHF patients
had died of HF-related causes within 3 years of cancer
registration.
Of note, of the IAHF patients, 70.6% of patients had died of
HF-related causes within the ﬁrst year following their HF
diagnosis.
Discussion
In this analysis of linked hospital administration data, we have
examined the patient journey through cancer diagnosis, che-
motherapy, and the onset of HF and ultimately HF-related
death. We have described and compared individuals who
had an index HF hospital admission (IAHF) with those who
did not have an index HF hospital admission (NIAHF) following
chemotherapy. All of the patients included in the analyses died
of HF-related causes. Speciﬁcally, we were interested in those
patients who died of HF-related causes but were not newly
diagnosed (index admission) or already had a HF diagnosis.
When comparing characteristics of the IAHF and NIAHF
patients, the median age and gender differences for the IAHF
patients had similar demographical characteristic to HF in the
non-cancer population.11 That is, the study group had a similar
median age and a greater proportion of men.11 In contrast,
NIAHF patients were younger and had a greater proportion
of female patients than males. In addition, there was a greater
proportion of patients with breast cancer in the NIAHF pa-
tients compared with the IAHF group. Collectively, our results
indicated that younger, female patients with breast cancer
died of HF-related causes before hospital admission for HF-
related causes.
The ﬁrst year following an index HF admission saw the
highest mortality, with 71% of individuals dying of HF-related
causes in that period. The ﬁrst year after cancer diagnosis
showed very similar proportions of patients in both groups
dying from HF-related causes (30.5 and 33.4% in the IAHF
and NIAHF, respectively). Without supplementary informa-
tion (refer to the Strengths and limitations section in the
succeeding texts), it is difﬁcult to further explore this ﬁnding
in more depth. It may be that IAHF patients are symptomatic
Table 1 Demographics, hospitalization, and chemotherapy rates for patients who died of HF-related causes by index admission for HF
Characteristics
Patient with index HF admission
N=279 (38.0)
Patient with no admission for HF
N=455 (62.0) P*
Median age (at cancer diagnosis) IQR 71.0 years (62–78) 66.0 years (56–74) <0.001
Age group
<20 years 1 (0.4) 3 (0.7) <0.001
20–29 years 1 (0.4) 5 (1.1)
30–39 years 3 (1.1) 17 (3.7)
40–49 years 11 (3.9) 49 (10.8)
50–59 years 31 (11.1) 80 (17.6)
60–69 years 78 (28.0) 128 (28.1)
≥70 years 154 (55.2) 173 (38.0)
Sex
Female 117 (41.9) 251 (55.2) 0.001
Male 162 (58.1) 204 (44.8)
Marital status
Married/de facto 160 (57.3) 273 (60.0) 0.487
Single/divorced/widowed 119 (42.7) 182 (40.0)
Country of birth
Australia 195 (69.9) 337 (74.1) 0.234
All other countries 84 (30.1) 118 (25.9)
Indigenous status
Indigenous 3 (1.1) 10 (2.2) 0.389
Non-Indigenous 276 (98.9) 445 (97.8)
Residence (postcode)
Metropolitan 244 (87.5) 379 (83.3) 0.138
Rural/remote 35 (12.5) 76 (16.7)
Cancer morphology/site
Breast 34 (12.2) 128 (28.1) <0.001
Haematological 245 (87.8) 327 (71.9)
Median no. of hospitalization (IQR) 7 (3–13) 6 (2–12) <0.001
Median no. of chemotherapy separations (IQR) 4 (2–9) 6 (2–12) <0.001
IQR, interquartile range (25th–75th percentile); SMR, standardized mortality ratio.
*Data were considered signiﬁcantly different at P ≤ 0.05.
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and mortality is high shortly after admission. A possible
explanation of similar mortality in NIAHF (typically younger
patients) is a higher tolerance of HF symptoms and as such
were not admitted to hospital, and sudden death followed
because of arrhythmia. Nonetheless, our results are compa-
rable with other studies that have demonstrated that 38%
of patients with a HF diagnosis had died within 12months.12
Although not statistically signiﬁcant, the risk of crude HF mortal-
ity was about 10% higher for individuals not admitted to hospital
with HF compared with those admitted with HF. Whilst it may
seem counterintuitive, and one might expect the NIAHF group
to have a lower proportion of mortality because of HF, a possible
explanation could be that those diagnosed with HF received
some intensive cardiac interventions that reduced theirmortality
Figure 2 Time to HF-related death after cancer diagnosis between those who had an index admission for HF (IAHF, n = 279) compared with those who
did not (NIAHF, n = 455).
Table 2 Adjusted time-varying Cox proportion hazards model for HF-related mortality of chemotherapy receiving patients with haema-
tological and breast cancer by index admission for HF
Patient with index HF admission Patient with no HF admission
Parameter HR (95% CI) P* HR (95% CI) P*
Age
<20 yearsa
20–29 years 0.30 (0.02–5.08) 0.408 0.56 (0.13–2.38) 0.435
30–39 years 0.26 (0.03–2.56) 0.246 0.47 (0.14–1.67) 0.245
40–49 years 0.33 (0.04–2.66) 0.295 0.49 (0.15–1.61) 0.240
50–59 years 0.35 (0.05–2.64) 0.307 0.57 (0.18–1.83) 0.343
60–69 years 0.46 (0.06–3.40) 0.447 0.44 (0.14–1.40) 0.165
≥70 years 0.44 (0.06–3.19) 0.413 0.50 (0.16–1.58) 0.237
Sex
Female vs. male 1.22 (0.89–1.68) 0.221 0.96 (0.75–1.23) 0.754
Marital status
Married/de facto vs. all other 0.96 (0.72–1.29) 0.802 0.98 (0.80–1.21) 0.869
Country of birth
Australia vs. all other 0.86 (0.65–1.14) 0.303 1.15 (0.92–1.44) 0.214
Cancer site
Breast vs. haematological 1.47 (0.97–2.23) 0.068 1.48 (1.11–1.95) 0.006
Chemotherapy separations (quintiles)
1–3a
4–6 0.91 (0.83–0.99) 0.027 0.97 (0.90–1.05) 0.420
7–9 0.93 (0.83–1.02) 0.152 0.94 (0.87–1.01) 0.102
10–16 0.92 (0.84–1.02) 0.108 0.98 (0.91–1.06) 0.684
≥17 0.95 (0.86–1.06) 0.364 0.97 (0.90–1.05) 0.479
HF, heart failure; HR, hazard ratio.
aReference category.
Data were adjusted for age, sex, marital status, country of birth, cancer site, and time-dependent number of chemotherapy treatment.
*Statistically signiﬁcant at P ≤ 0.05.
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risk in the ﬁrst year. It is possible that extracardiac treatment is
also responsible for comparable proportions of mortality be-
cause of HF at the end of 3 years also (60 and 62% in the IAHF
and NIAHF, respectively). These mortality rates are all substan-
tially higher, within all age groups within this cohort, than those
reported in the most recent epidemiological studies for HF in
the general population where, although survival has improved,
the absolute mortality rates for HF remain approximately 50%
within 5 years of diagnosis.13,14 In the ARIC study, the 30-day,
1-year, and 5-year case fatality rates after hospitalization for
HF were 10.4, 22, and 42.3%, respectively.15
Over the course of their treatment, IAHF patients received
signiﬁcantly fewer chemotherapy treatments than the NIAHF
group. This trend could be attributed to clinical adherence to
cardiotoxicity treatment guidelines, with a commensurate
reduction in cumulative chemotherapy dose or complete
cessation of treatment after HF was identiﬁed.5 However, in
the context of a retrospective observational study, there are
numerous confounders that were beyond our control that
would need to be accounted for to deﬁnitively conclude if
this was the case. In addition, we may need to consider that
current available therapies for HF administered earlier in the
chemotherapy treatment phase are of limited efﬁcacy. Also,
our outcomes may be indicating that the admission index
was a poor surrogate for efﬁcacy of early introduction of
effective therapies.
Strengths and limitations
The strengths of this study are the large sample size and the
inclusion of virtually all patients with cancer who underwent
chemotherapy over a 14-year period. The ability to link
administrative datasets allows for the integration of multiple
databases to provide a comprehensive picture of patient out-
comes. However, potential limitations should be considered.
The nature of this type of study method means that what is
gained in overall numbers of patients comes at the expense of
detailed case information. The direct implication of this is that
numerous confounding factors cannot be accounted for. For
example, the absence of information regarding the cancer
treatment, including the precise chemotherapy drugs used
and the site and extent of irradiation, plus radiotherapy and
the lack of information about pre-existing cardiovascular risk
factors or established heart disease prevents us from under-
standing the association of speciﬁc treatments and the subse-
quent development of HF. Furthermore, in the absence of
supplementary data, we are unable to elucidate the causes
of HF-related deaths (e.g. was death as a result of advanced
cardiomyopathy, cardiogenic shock, arrhythmia, or electrolytes
imbalance because of diuretics?) or the severity of HF status.
These limitations were because of only being able to access
datasets with custodian approval, and in an idealized situation,
more relevant data would have been incorporated in the
analysis framework (e.g. whether patients were administered
appropriate and optimal HF medications). In the absence of
this data, we included chemotherapy separations as a surro-
gate for drug information. The gender balance in our study is
not representative of the general population with 31% of the
sample being male and 69% female. The inclusion of patients
with breast cancer has resulted in an over-representation of
female patients.
Clinical implications
Current Clinical Practice Guidelines for cardiovascular toxicity
after chemotherapy and radiotherapy from the European
Society of Medical Oncology (ESMO) recommend that pa-
tients are frequently monitored for cardiovascular risk be-
fore, during, and after treatment.5 These guidelines state
that both cardiovascular risk factor screening and heart struc-
ture and function monitoring, including appropriate cardio-
vascular intervention, should occur prior to cancer
treatment. In addition, cardiac monitoring should continue
at baseline, 3, 6, and 9months during treatment, and further
monitoring should be undertaken at 12 and 18months and
followed up at 4 and 10 years. In the present study, we have
identiﬁed that HF-related death can occur rapidly after can-
cer treatment in individuals diagnosed with cancers in which
cardiotoxic drugs are often prescribed. This ﬁnding is
consistent with the ESMO recommendations of ongoing car-
diac monitoring, and it is likely with ongoing frequent moni-
toring appropriate intervention can be implemented to
decrease HF-related mortality after cancer therapy.
Conclusions
The proﬁle of patients who died of HF-related causes who
had an IAHF after cancer treatment matched the current
proﬁle of HF in the general population (over half were aged
≥70 years). However, the group that did not have an index
admission for HF were younger (62% were aged ≤69 years),
females with breast cancer. In this group, HF after cancer
therapy may have been underdiagnosed or undertreated
until death, and the HF caused by the chemotherapy may
manifest long after discharge from cancer care.
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